Literature DB >> 18093232

IGF-1, IGFBP-3, VEGF and MMP-9 levels and their potential relationship with renal functions in patients with compensatory renal growth.

Bilal Yildiz1, Nurdan Kural, Omer Colak, Ilknur Ak, Nevbahar Akcar.   

Abstract

BACKGROUND: Mechanisms of compensatory renal growth (CRG) still remain a mystery. Various growth factors, including growth hormone, insulin-like growth factor-1 (IGF-1) have been implicated in different forms of CRG. AIMS: To investigate the serum levels of IGF-1, vascular endothelial growth factor (VEGF - role in vascular remodelling), matrix metalloproteinase-9 (MMP-9 - essential for normal nephrogenesis) and correlation of renal function in patients with unilateral nephrectomized, agenesis and hypoplasic kidney.
METHODS: Thirty patients were included in this study. In group I, there were 10 patients with unilateral nephrectomy, while in group II, there were 10 patients with unilateral agenesis. As for group III, there were 10 patients with unilateral hypoplastic kidney. The serum levels of IGF-1, IGF-binding protein-3 (IGFBP-3), VEGF and MMP-9 were studied in all the cases. Clearance of creatinin (Ccr) and protein excretion were examined in the 24 h urine. CRG was determined with ultrasonography and scintigraphy. Twenty-six control subjects were also studied.
RESULTS: The levels of IGF-1, IGFBP-3, VEGF and MMP-9 were significantly higher in patients than in the control subjects (P < 0.001). Ccr and protein excretion levels were different in study groups than in those of the control group (P < 0.01). There were positive correlations between the serum levels of IGF-1 with IGFBP-3; IGF-1 with MMP-9; IGFBP-3 with MMP-9 (r = 0.825, P = 0.0001; P < 0.001 r = 0.611; P < 0.001 r = 0.585, respectively). There were negative correlations between GFR and the serum levels of IGF-1, IGFBP-3 and MMP-9 (P < 0.01 r = -0.708; P = 0.002 r = -0.803; P < 0.05 r = -0.442, respectively). Furthermore, there were positive correlations between proteinuria and the serum levels of IGF-1, IGFBP-3 and MMP-9 (P = 0.039 r = 0.600; P < 0.05 r = 0.456; P < 0.05 r = 0.424).
CONCLUSIONS: Increased IGF-1, IGFBP-3, VEGF and MMP-9 were observed in CRG in the follow-up period. IGF-1 and MMP-9 seemed to have increased in patients with CRG in defiance of the development of fibrosis. Moreover, IGF-1 and MMP-9 seem to be associated with reduced renal function and proteinuria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093232     DOI: 10.1111/j.1475-097X.2007.00783.x

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  5 in total

1.  Change in renal function following laparoscopic donor nephrectomy using 99 mTc-diethylenetriaminepentaacetic acid scan.

Authors:  Hyuk Jin Cho; Sae Woong Choi; Woong Jin Bae; Su Jin Kim; Sung Hoo Hong; Ji Youl Lee; Sae Woong Kim; Tae-Kon Hwang
Journal:  World J Urol       Date:  2014-09-25       Impact factor: 4.226

2.  Renal carcinogenesis after uninephrectomy.

Authors:  Yi Sui; Hai-Lu Zhao; Heung Man Lee; Jing Guan; Lan He; Fernand Mm Lai; Peter Cy Tong; Juliana Cn Chan
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

3.  Uteroplacental insufficiency affects kidney VEGF expression in a model of IUGR with compensatory glomerular hypertrophy and hypertension.

Authors:  Mariana Baserga; Allyson L Bares; Merica A Hale; Christopher W Callaway; Robert A McKnight; Pascale H Lane; Robert H Lane
Journal:  Early Hum Dev       Date:  2009-02-01       Impact factor: 2.079

4.  Impact of menopausal status on kidney adaptation after unilateral nephrectomy for kidney donation in women.

Authors:  Pierre-Yves Charles; Marion Vallet; Renaud De La Faille; Pierre Merville; Séverine Lagarde; Nicolas Grenier; Claire Lebely; Benoît Lepage; Julien Allard; Nassim Kamar; Ivan Tack
Journal:  J Nephrol       Date:  2021-06-01       Impact factor: 3.902

Review 5.  Human conditions of insulin-like growth factor-I (IGF-I) deficiency.

Authors:  Juan E Puche; Inma Castilla-Cortázar
Journal:  J Transl Med       Date:  2012-11-14       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.